Fulcrum Therapeutics Inc. has released a corporate presentation detailing its strategic focus on developing oral small molecules aimed at modifying gene expression in rare diseases, particularly in the field of benign hematology. The presentation highlights Pociredir, a potential best-in-class oral small molecule for inducing fetal hemoglobin (HbF) in sickle cell disease $(SCD)$, which has received Fast Track and Orphan Drug Designations. Data disclosure for Phase 1b PIONEER trial cohorts is planned for early Q3 2025 and year-end 2025. Additionally, the company plans to submit an Investigational New Drug $(IND.AU)$ application in Q4 2025 and reports a cash position of $226.6 million as of March 31, 2025, providing a financial runway into at least 2027. You can access the full presentation through the link below.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。